Clinical Trial Update: Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating intrathecal busulfan for leptomeningeal tumors has completed, assessing safety and dosing in patients with recurrent or refractory di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Carcinomatosis

Drugs mentioned

• BUSULFAN (Busulfan)

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED